Observational studyPediatric nephrology (Berlin, Germany)2025
Pediatric acute kidney injury is associated with impairment in nicotinamide adenine dinucleotide (NAD+) metabolism.
Observational study in Pediatric nephrology (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Therapeutic remodeling of the ceramide backbone prevents kidney injury.Cell metabolism · 2026Article
- Acute kidney injury is associated with elevated urinary endotrophin.American journal of physiology. Renal physiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAcute kidney injury (AKI) is highly prevalent among hospitalized children, but there is no treatment. Impaired de novo nicotinamide adenine dinucleotide (NAD+) biosynthesis measured via elevation of the urine quinolinic acid-to-tryptophan ratio (uQ:T) is a feature of AKI that has been described in preclinical models and humans with AKI. Small prospective trials to restore NAD+ abundance with NAD+ precursor supplementation have shown promise in the prevention and treatment of AKI. It is not known whether pediatric patients also develop suppression of NAD+ biosynthesis during AKI, but such information will be critical before children can be included in NAD+ -based clinical trials to treat or prevent AKI.
methodsAn observational cross-sectional study was performed on convenience urine samples from children hospitalized in a tertiary care children's hospital. Samples were split into five groups: outpatient controls, floor controls, ICU controls, floor AKI, and ICU AKI. Clinical data were collected from the medical record, and metabolites were measured using targeted mass spectrometry. Patients with AKI were compared to their respective controls. A multivariate linear regression was used to assess whether demographic variables were independently associated with uQ:T, and odds of AKI were assessed in serial uQ:T tertiles using multivariate logistic regression models that adjusted for patient variables.
resultsSixty-nine control patients (39 outpatient, 10 floor, and 20 ICU controls) and 22 AKI patients (12 floor and 10 ICU) were enrolled. uQ:T was elevated in patients with AKI compared to their respective controls. No demographic variables were independently associated with uQ:T, and when adjusting for patient demographic and clinical variables, the odds of AKI increased serially with uQ:T tertile.
conclusionsElevated uQ:T is a feature of pediatric AKI. The present results warrant further exploration in observational and potentially interventional studies with NAD+ precursor therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.